Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1644 1646 1674
This examiner grants 57% of resolved cases
Dennis John Sullivan examines cases in Art Unit 1642 of Tech Center 1600. A total of 114 resolved cases are included in the data for this profile. The 57.9 percent allowance rate shows the portion of resolved applications that result in a grant. The 49.1 percent lift indicates the increase in the probability of a grant following an interview. This lift is a comparison to the baseline allowance rate of 57.9 percent. Practitioners can use the 49.1 percent figure to evaluate the impact of direct communication.
The median time to allowance is 1363 days. This 1363-day timeframe measures the span from application to patent issuance. Art Unit 1642 is the group where these 114 resolved cases were processed. Tech Center 1600 provides the broader organizational context for the examiner's work. Practitioners can use these metrics to set expectations for the length of the prosecution cycle. The data provides a basis for evaluating the impact of interviews during the patent application process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18038321 | USE OF INSULIN-LIKE GROWTH FACTORS WITH GAMMA-CHAIN CYTOKINES TO INDUCE HOMEOSTATIC PROLIFERATION OF LYMPHOCYTES | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 18216026 | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer | Non-Final OA | Janssen Biotech, Inc. |
| 18300288 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone | Non-Final OA | Janssen Biotech, Inc. |
| 18020515 | PLASMA EXCHANGE REMOVAL OF SPD-L1 | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17769171 | COMPOSITIONS AND METHODS FOR DETECTING PLXDC1 AND PLXDC2 IN HUMAN TISSUES | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17286083 | Methods to Diagnose and Treat Cancer Using Non-Human Nucleic Acids | Final Rejection | The Regents of the University of California |
| 18565023 | COMPOSITIONS AND METHODS TO TRANSFECT, TEST, AND TREAT SKIN CELLS | Non-Final OA | The Regents of the University of Michigan |
| 18264799 | METHODS OF TREATING CANCER BY ADMINISTERING A NEOADJUVANT PD-1 INHIBITOR | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17517567 | USE OF ISATUXIMAB FOR THE TREATMENT OF MULTIPLE MYELOMA | Final Rejection | Sanofi-Aventis U.S. LLC |
| 17797916 | COMPOSITION COMPRISING CHEMOKINE INHIBITOR, COLONY STIMULATING FACTOR INHIBITOR, AND CANCER IMMUNOTHERAPY AGENT FOR PREVENTION OR TREATMENT OF CANCER AND COMBINATION THERAPY | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18461081 | NIDOGEN 1 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET OF HEPATOCELLULAR CARCINOMA, COMPOSITION AND METHODS THEREOF | Final Rejection | THE UNIVERSITY OF HONG KONG |
| 17909310 | ANTI-CCR8 AGENTS | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 18558505 | METHODS OF TREATMENT OF AUTOIMMUNE DISORDERS USING ILT7 BINDING PROTEINS | Non-Final OA | Viela Bio, Inc. |
| 17282580 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MUCOSAL INFLAMMATORY DISEASES | Non-Final OA | Enios Applications Private Limited Company |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy